The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 105 results:
Author [ Title(Desc)] Type Year
Filters: Author is Katsiki, Niki  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Doumas, M., Katsiki N., & Papademetriou V. (2018).  Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?. Angiology. 69(1), 5-9.
R
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Reaching hypertriglyceridemia goals.. Curr Med Res Opin. 30(3), 391-3.
Mantelas, M., Katsiki N., Antonitsis P., Kyurdzhieva E., Mikhailidis D. P., & Hatzitolios A. (2011).  Rectus sheath hematoma: a simplified emergency surgical approach.. Open Cardiovasc Med J. 5, 4-5.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.. Am J Cardiol. 110(5), 763.
Gossios, T. D., Ziakas A., Doumas M., Katsiki N., Petroglou D., Kouparanis A., et al. (2014).  Renal denervation: transition from pathophysiology to clinical practice.. Angiology. 65(9), 760-8.
Kargiotis, K., Athyros V. G., Giouleme O., Katsiki N., Katsiki E., Anagnostis P., et al. (2015).  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.. World J Gastroenterol. 21(25), 7860-8.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'.. Clin Cardiol. 35(5), 315; author reply 316-7.
Antonopoulou, V., Karras S. N., Koufakis T., Yavropoulou M., Katsiki N., Gerou S., et al. (2019).  Rising Glucagon-Like Peptide 1 Concentrations After Parathyroidectomy in Patients With Primary Hyperparathyroidism.. J Surg Res. 245, 22-30.
Katsiki, N., Georgiadou E., & Hatzitolios A. I. (2009).  The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.. Drugs. 69(11), 1417-31.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  The role of statins in the treatment of type 2 diabetes mellitus: an update.. Curr Pharm Des. 20(22), 3665-74.
S
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2017).  Semaglutide, lipid-lowering drugs, and NAFLD.. Lancet Diabetes Endocrinol. 5(5), 329-330.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention.. Curr Med Res Opin. 31(2), 191-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown). 13(4), 254-9.
Katsiki, N., Athyros V. G., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2014).  Should we expand the concept of coronary heart disease equivalents?. Curr Opin Cardiol. 29(4), 389-95.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial.. J Hepatol. 57(2), 476.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2015).  Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly.. Atherosclerosis. 238(2), 182-4.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opin Investig Drugs. 22(9), 1089-93.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.. Curr Pharm Des. 22(18), 2723-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
T
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
Katsiki, N., Kollari E., Dardas S., Dardas P., Haidich A-B., Athyros V. G., et al. (2016).  Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study.. Open Cardiovasc Med J. 10, 64-8.
Katsiki, N., Koumaras C., Athyros V. G., & Karagiannis A. (2012).  Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk.. Angiology. 63(1), 9-11.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.